In addition, high MALAT1 expression is associated with inadequate response to oxaliplatin-based chemotherapy by suppressing E-cadherin signaling and promoting epithelial-mesenchymal transition in CRC patients [36, 65]. This evidence concerns the gene CDH1 and colorectal carcinoma.